Utah Medical Products, Inc.

NASDAQ:UTMD

Medical - Instruments & Supplies

Healthcare
$72.24 +1.67%

+$1.10 today

Market cap
$205.81M
Beta
0.37
P/E (TTM)
19.6
EPS (TTM)
$3.41
Dividend yield
1.85%
52W Low $52.00High $71.81

Volume 0.02M

Average 0.01M

UTMD EBITDA Margin

EBITDA as a percentage of revenue.

Utah Medical Products, Inc.NASDAQ: UTMD

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 44.4%

EBITDA Margin was 44.4% in Q1 FY2026, up 1.2 pp from a year earlier. On a trailing-twelve-month basis it was 43.6%, down 2.2 pp year over year. Over 3 fiscal years it narrowed by 8.8 pp.

Context

  • EBITDA Margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
44.4%+1.8 pp QoQ
Last fiscal yearDec 2025
44.3%-3.6 pp YoY
LTMMar 2026
43.6%-2.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.2 pp——
1 year-3.6 pp——
3 years-8.8 pp——
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
44.3%
Year-over-year change
-3.6pp

EBITDA Margin vs competitors

How UTMD compares with its peers on the latest reported figures

  • UTMD's LTM Mar 2026 EBITDA Margin of 43.6% is the highest of the 11 companies compared; the peer median is -50.9%.
  • Its year-over-year change of -2.2 pp is the 8th highest of 11, against a peer median of +13.4 pp.
  • Over three fiscal years its change of -8.8 pp compares with a peer median of +23.9 pp.
UTMD Competitors Peer median
EBITDA Margin for UTMD and competitors
Company Period LTM level YoY 3-year change
UTMDUtah Medical Products, Inc.LTM Mar 202643.6% -2.2 pp-8.8 pp
PLXProtalix BioTherapeutics, Inc.LTM Mar 202629.2% +17.2 pp+17.0 pp
INFUInfuSystem Holdings, Inc.LTM Mar 202618.2% +2.6 pp+4.0 pp
KRMDKORU Medical Systems, Inc.LTM Mar 2026-3.4% +9.6 pp+31.8 pp
STIMNeuronetics, Inc.LTM Mar 2026-17.0% +26.6 pp+30.8 pp
PREPrenetics Global LimitedLTM Mar 2026-45.4% +91.4 pp+1621.5 pp
OSUROraSure Technologies, Inc.LTM Mar 2026-56.4% -42.7 pp-49.1 pp
PROFProfound Medical Corp.LTM Mar 2026-200.6% +96.6 pp+145.4 pp
CHRSCoherus Oncology, Inc.LTM Mar 2026-341.0% -291.0 pp-282.5 pp
NYXHNyxoah S.A.LTM Mar 2026-472.8% +983.8 pp+76.9 pp
CATXPerspective Therapeutics, Inc.LTM Mar 2026-17902.8% -12192.4 pp-11194.0 pp
Peer median (excluding UTMD) -50.9%+13.4 pp+23.9 pp

Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.05M52.28M50.22M40.9M38.52M
Cost of Revenue18.14M20.09M20.19M16.76M18.65M
Gross Profit30.92M32.2M30.04M24.14M19.88M
Gross Margin63.0%61.6%59.8%59.0%51.6%
Research & Development526K493K560K813K668K
Selling, General & Admin11.51M11.91M12.7M5.57M7.81M
Operating Expenses12.04M12.41M13.26M10.55M8.47M
Depreciation & Amortization7.28M7.08M6.37M2.77M2.95M
EBITDA26.35M27.74M24.75M19.57M17.06M
EBITDA Margin53.7%53.1%49.3%47.9%44.3%
Operating Income18.88M19.79M16.78M13.59M11.4M
Operating Margin38.5%37.9%33.4%33.2%29.6%
Interest Income166K661K03.37M0
Interest Expense00000
Other Income / Expenses181K869K3.31M3.21M2.71M
Income Before Tax19.06M20.66M20.09M16.8M14.11M
Pre-Tax Margin38.9%39.5%40.0%41.1%36.6%
Income Tax Expense4.27M4.19M3.45M2.93M2.82M
Net Income14.79M16.47M16.64M13.87M11.29M
Net Margin30.1%31.5%33.1%33.9%29.3%
EPS (Basic)4.054.534.573.963.41
EPS (Diluted)4.044.524.573.963.48
Weighted Avg Shares3.65M3.64M3.64M3.5M3.31M
Weighted Avg Shares (Diluted)3.66M3.64M3.64M3.5M3.24M

Utah Medical Products, Inc.

NASDAQ:UTMD

Intrinsic Alpha fair value

Locked

Current Price

$72.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.